Plozasiran, an investigational drug, significantly reduced triglyceride levels in patients at risk for pancreatitis. In the phase 2 SHASTA-2 study, most patients saw their levels fall below the pancreatitis risk threshold after receiving plozasiran injections. The drug’s safety profile was generally favorable, but it did lead to increased LDL cholesterol and a temporary decline in glycemic control in diabetic patients. A phase 3 trial with a 25-mg dose is planned. While the LDL increase was unexpected, it can be managed with statins. The study results show promise for a new treatment for severe hypertriglyceridemia.
Source link
Substantial Triglyceride Reduction With Plozasiran
